Featured Story | Monday, June 22, 2020 Gilead Sciences’ antiviral remdesivir, given intravenously, currently holds an FDA emergency use authorization to treat severe hospitalized COVID-19 patients. Now, the company is hoping a new inhaled formulation could get it into earlier stages of the respiratory disease. read more |
| |
|---|
|
Top Stories Monday, June 22, 2020 While these supports were proliferating before COVID-19, they’re proving their value now, especially as more people work remotely, according to a new survey. read more Monday, June 22, 2020 About 6 months into the pandemic and about 130 days until the U.S. presidential election, COVID-19 vaccines are moving ahead at record speeds. Now, a group of analysts predict “at least one” vaccine will be approved before November 3. read more Monday, June 22, 2020 Patient volumes are rising for healthcare facilities, but a looming deadline for loan repayments and a change in payer mix spell trouble, Moody's says. read more Monday, June 22, 2020 While it waits for the regulatory go-ahead on a partnership with Merck, Ridgeback Biotherapeutics is wasting no time. The Miami-based biotech is kicking off two phase 2 trials of its antiviral treatment, the first in hospitalized COVID-19 patients and the second in patients newly diagnosed with COVID-19 who are still at home. read more Monday, June 22, 2020 Abbott Lab's COVID-19 quick test has come under fire—again. Now, critics want to know why the FDA approved the test. The U.K will study a new, swabless COVID test, and Gilead will test an inhalable form of remdesivir in early COVID-19. Plus, Chinese researchers found that antibodies in recovered COVID patients fell after three months. read more Monday, June 22, 2020 Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more Monday, June 22, 2020 The road for hydroxychloroquine against COVID-19 is coming to an end as three major clinical programs by the World Health Organization, the NIH and Novartis have been terminated after a U.K. trial found “no clinical benefit” for the malaria drug championed by President Donald Trump. read more Monday, June 22, 2020 The U.K. government will begin testing a new, swabless coronavirus test, designed to be completed at home on a weekly basis by spitting into a collection tube. read more Monday, June 22, 2020 The science around COVID-19, the tests to detect its antibodies and treatments to fight it are still evolving. But it seemed worthwhile to give convalescent plasma donation a try. read more Monday, June 22, 2020 Harvard Pilgrim Health Care is making $32 million in premium credits available to assist its employers and members in navigating the costs of COVID-19. read more Monday, June 22, 2020 Epidarex Capital raised £102.1 million ($126 million) in its third fund. It will bankroll life sciences companies from “emerging hubs” across the U.K., investing £2 million to £5 million at a time. read more |
|
.jpg)
